Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Navidea Biopharma (NAVB) Reports Q4 Loss of $0.02
March 7, 2019 4:28 PM ESTNavidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.02), versus ($0.04) reported last year. Revenue for the quarter came in at $119.32 thousand, versus $391.49 thousand reported last year.
Navidea had a productive quarter as we advanced the business and our novel imaging pipeline, said Mr. Jed A.... More
